BASF's Ludwigshafen Setback Compounds Evonik Deal Uncertainty
Published on 09/30/2026 at 07:10 | Editorial boerse-global.de
BASF is grappling with two distinct challenges at once: a technical failure at its flagship Ludwigshafen site and the delicate dance of a rejected takeover approach for Evonik Industries. The combination has left investors weighing operational reliability against strategic ambition.
Cracker Defect Forces Flaring at Main Plant
On Tuesday, the chemicals giant disclosed an unplanned outage at a key unit of its headquarters complex. A technical fault in a steam cracker — the backbone of petrochemical feedstock production — has forced BASF to flare excess gas. According to the company, visible flaring, soot emissions, and noise disturbance could persist through the end of the week.
The timing could hardly be worse. Just last week, an explosion during maintenance work at the site left two employees of an external contractor with burn injuries. Disruptions at such large-scale installations can ripple through downstream production chains, adding a layer of operational risk that management must contain while simultaneously pursuing a multi-billion-euro acquisition.
Evonik Board Rebuffs Initial Overture
Media reports indicate that Evonik's supervisory board turned down BASF's first offer of EUR 22.15 per share. Handelsblatt pegged the proposed transaction at EUR 10.3 billion, a figure the board deemed insufficient. BASF declined to comment on the offer's size.
Should investors sell immediately? Or is it worth buying BASF?
The Ludwigshafen-based group confirmed exploratory talks about a potential acquisition last Friday but described both the progress and the outcome as open-ended. Whether — and when — a revised bid might materialize remains unclear. Handelsblatt also floated the possibility of a share swap between the DAX-listed company and RAG-Stiftung, Evonik's anchor shareholder, as an alternative structure.
Market Response: Caution Over Costly Expansion
Equity investors have reacted coolly to the mix of operational hiccups and expensive acquisition speculation. BASF shares were down 0.9% on Tuesday at EUR 49.80, hovering only marginally above the 200-day moving average of EUR 49.56. The prior session closed with a milder 0.7% decline at EUR 49.94.
Sentiment among market participants leans skeptical toward large-scale deals in a demanding industry climate. The fear is straightforward: if BASF must sweeten its bid for Evonik, additional financial strain could follow. The rejected EUR 10.3 billion valuation merely sets the floor for negotiations. Every extra euro per Evonik share raises the funding requirement and narrows the room for other investments.
The pivotal question over the coming weeks is what price can secure agreement with Evonik and RAG-Stiftung without overstretching BASF's balance sheet. Should the other side demand a significant premium, BASF risks overpaying for synergies. Management's willingness to walk away from excessive demands would reinforce confidence in financial discipline; a forced deal would likely amplify market skepticism.
Analyst Views Diverge on Risk-Reward
Opinions on the stock remain split. Bernstein Research's James Hooper trimmed his price target to EUR 61 from EUR 63 on Monday while maintaining an "Outperform" rating — a signal of confidence that the strategic direction will pay off over the medium term. Deutsche Bank Research also kept its "Buy" rating with an unchanged EUR 60 target.
On the bearish side, Chetan Udeshi of J.P. Morgan reiterated an "Underweight" rating with a EUR 40 target on Monday. A costly takeover in a challenging sector environment, he suggests, could weigh on earnings power for years to come.
BASF at a turning point? This analysis reveals what investors need to know now.
Agricultural Unit Restructuring Offers a Counterweight
Part of the bull case rests on BASF's parallel corporate overhaul. Roughly a week ago, the company announced organizational measures in its Agricultural Solutions segment aimed at streamlining decision-making and preparing the business for transformation into a standalone entity. If that carve-out proceeds as planned, it could free up balance-sheet capacity for targeted portfolio adjustments.
Chart technicians are watching the 200-day moving average closely. As long as the stock holds above EUR 49.56 on a closing basis, the medium-term uptrend remains intact; a sustained break below that level would risk extending the consolidation.
On the operational front, the ongoing IFSCC congress in Perth — running through October 1 — is offering insights into research on sustainable extraction and biopolymers. Yet the next decisive catalyst for the share price is whether BASF raises its offer for Evonik or walks away from the table without a deal.
Ad
BASF Stock: New Analysis - 30 September
Fresh BASF information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
